We found nSMase2 expression and activity to be increased in COPD-derived specimens and demonstrated attenuated IL-33–driven type 2 inflammation under conditions of nSMase2 blockade in an Alternaria model. This evidence concerns the gene IL33 and chronic obstructive pulmonary disease.